// added the section below on July 01 2024 // till here on July 01 2024

Vascular Disrupting Agents Market

Vascular Disrupting Agents Market by Type of Indications, Type of Therapeutic Area, Type of Molecules, Type of Therapy, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2030

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    295

  • View Count
    12188

Vascular Disrupting Agents Market Overview

The global vascular disrupting agents market size is estimated to grow from USD 23 million in 2021 to USD 2 billion by 2030, representing a CAGR of 65% during the forecast period 2021-2030.

Further, 90% of all diagnosed cancers are solid tumors  and a large number of the novel anticancer therapies are being developed for the treatment of these cancers. In the last five years, the United States Food and Drug Administration (USFDA) has approved more than 100 drugs for the treatment of different types of cancer. However, as the global population is gradually being exposed to a growing list of risk factors and cancer-causing agents, there is a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition.

Given the inherent nature of solid tumors to form rapidly growing masses of malignant cells, angiogenesis and adequate blood supply is critical to the survival of the bulk tumor population. Therefore, tumor vasculature continues to be an attractive and promising therapeutic target. Vascular disrupting agents (VDAs) are therapeutic interventions that target established tumor vasculature and thereby, disrupt blood flow to cancerous tissue. 

Presently, there are multiple small molecule VDAs, which have been / are being developed for the treatment of a variety of oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma and ovarian cancer. Moreover, combination therapies, involving VDAs and conventional chemotherapy, radiation therapy and radioimmunotherapy, have demonstrated excellent clinical responses in multiple animal models. It is worth noting that the R&D efforts in this field are being supported by the National Institutes of Health, accounting for USD 95 million in research grants disbursed since 2016. Driven by encouraging clinical research, this niche, but emerging domain, is poised to witness healthy market growth during the forecast period, with pioneers in the field likely to benefit from the first-to-market advantage.

Vascular-Disrupting-Agents-Market-Context-Roots-thumb Vascular-Disrupting-Agents-Market-Distribution-of-Developers-by-Size-and-Geography-Roots-thumb Vascular-Disrupting-Agents-Market-Distribution-by-Therapeutics-Area-Roots-thumb

Key Companies in Vascular Disrupting Agents Market 

Examples of key companies engaged in vascular disrupting agents market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AGC Biologics, Avid Bioservices, Bionomics, Mateon Therapeutics, Myrexis and VBL Therapeutics. This market report includes an easily searchable excel database of all the companies developing vascular disrupting agents, worldwide.

Scope of the Report

The ‘Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma,  Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter),  Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and  Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ market report features an extensive study of the current market landscape, market size, market share, market trends, market forecast, market outlook and future opportunities of the vascular disrupting agents market. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in vascular disrupting agents market, over the next decade.

Vascular-Disrupting-Agents-Market-Grant-Analysis-Roots-thumb Vascular-Disrupting-Agents-Market-Clinical-Reseasrch-Landscape-Roots-thumb Vascular-Disrupting-Agents-Market-Publication-Analysis-Roots-thumb

Amongst other elements, the market research report includes:

  • A detailed review of the current market landscape of vascular disrupting agents, including information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of product candidates, therapeutic area (hematological malignancies, solid tumors and others), target indication(s), type of molecule (small molecule (tubulin binding agents and flavonoids), and ligand directed agents), type of therapy (monotherapy, combination therapy and others) and route of administration (oral, intravenous and others). In addition, it presents a list of companies developing vascular disrupting agents and analysis based on year of establishment, company size and location of headquarters. 
  • Detailed profiles of the prominent players in vascular disrupting agents market (shortlisted on the basis of number of vascular disrupting agents in development pipeline). Each profile features a brief overview of the company, its financial information (if available), detailed description (including information on the type of drug, current status of development, target indications, mode of action and type of therapy) of their respective lead drug candidates, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various vascular disrupting agents, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of molecule, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus and key indications.
  • A detailed review of more than 750 peer-reviewed, scientific articles related to research on vascular disrupting agents, which have been published during the period, 2016 - January 2021. The publications have been analyzed to highlight the trends across year of publication, emerging focus areas, popular keywords, key indications, key therapeutic areas, key research journals and popular authors. 
  • An in-depth analysis of grants awarded to various research institutes for the projects related to vascular disrupting agents, in the period between 2016 and January 2021, on the basis of parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, and type of recipient organization, while highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A list of key opinion leaders (KOLs) within vascular disrupting agents market, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

The key objective of vascular disrupting agents market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for vascular disrupting agents market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the forecast period 2021-2030.

The market report also features the likely distribution of the current and forecasted opportunity across [A] target indications (chemotherapy-induced neutropenia, glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma,  non-small cell lung cancer, prostate cancer, recurrent platinum resistant ovarian cancer, transitional cell cancer of renal pelvis and ureter), [B] therapeutic area (hematological malignancies, solid tumors and other therapeutic areas), [C] type of molecule (small molecule and ligand-directed agents), [D] type of therapy (monotherapy, combination therapy and both), [E] route of administration (oral, intravenous), and [F] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World).

In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are vascular disrupting agents?

Answer: Vascular disrupting agents (VDAs) are therapeutic interventions that target established tumor vasculature and thereby, disrupt blood flow to cancerous tissue.

Question 2: How big is the vascular disrupting agents market?

Answer: The vascular disrupting agents market size is estimated to be worth $23 million in 2021.

Question 3: What is the projected market growth of the vascular disrupting agents market?

Answer: The vascular disrupting agents market is expected to grow at compounded annual growth rate (CAGR) of 65% during the forecast period.

Question 4: Who are the leading drug developers in the vascular disrupting agents market?

Answer: Examples of key companies engaged in vascular disrupting agents market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AGC Biologics, Avid Bioservices, Bionomics, Mateon Therapeutics, Myrexis and VBL Therapeutics.

Question 5: How many molecules are currently being developed by companies engaged in the vascular disrupting agents market?

Answer: Over 120 different molecules are currently being developed under various clinical and preclinical stages by companies engaged in the vascular disrupting agents market.

Question 6: How many articles have been published related to the vascular disrupting agents over the last few years?

Answer: More than 750 articles have been published related to the vascular disrupting agents between 2016 to 2020.

Question 7: Which region emerged as the hub for companies engaged in the vascular disrupting agents market?

Answer: North America emerged as the hub for companies engaged in the vascular disrupting agents market, with over 45% of the players established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com